Danzhu Wu

Danzhu Wu

Auto-generated profile, based on publicly available information

Danzhu Wu

Clinical Medical College of Jining Medical University, Jining, Shandong Province, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
PDPeng Dong
Peng Dong
YYYu Yan
Yu Yan
LYLiyuan Yang
Liyuan Yang
DWDanzhu Wu
Danzhu Wu
HWHui Wang
Hui Wang
XYXinshuang Yu
Xinshuang Yu
Objective. Immunotherapy has shown better efficacy and less toxicity than chemotherapy in the treatment of non-small-cell lung cancer (NSCLC) at advanced stage. This study evaluates the safety and efficacy of neoadjuvant immunotherapy for resectable NSCLC. Methods. Literature examination was performed by searching the PubMed, the Cochrane Library, and Embase for articles evaluating the efficacy and safety of neoadjuvant immunotherapy for resectable NSCLC. The 95 confidence interval (CI) and effect sizes (ES) were evaluated. Heterogeneity and subgroup analysis were performed. Meta-analysis was carried out using Stata BE17 software. Results. In total, 678 patients from eighteen studies were recruited in this meta-analysis. The pathological complete response (pCR) and major pathological response (MPR) were used to evaluate the efficacy of neoadjuvant immunotherapy. Significantly higher MPR values were observed in neoadjuvant immunotherapy (MPR:ES=0.44; 95 CI: 0.330.55; pCR:ES=0.22; 95 CI: 0.150.30) compared with neoadjuvant chemotherapy (MPR<25 and PCR:ES=215). Treatment-related adverse events (TRAE), surgical resection rate, surgical delay rate, and incidence of surgical complications were used to evaluate the safety. In summary, ES values for the incidence of TRAE, incidence of surgical complications, and surgical delay rate were 0.4, 0.24, and 0.04, respectively, that were significantly lower than those for neoadjuvant chemotherapy (95 CI: 0.040.90; 0.220.75; and 0.010.10, respectively). The mean surgical resection rate of 89 was similar to the reported 7590 resection rate with neoadjuvant chemotherapy (OR=7.61, 95 CI: 4.9011.81). Conclusion. Neoadjuvant immunotherapy is safe and effective for resectable NSCLC.